Research Goal Sample Clauses

Research Goal. The Genealogist is being hired to research the following: __________________________________________________________________________________ __________________________________________________________________________________ __________________________________________________________________________________ Contract acceptance. I, the client, __________________________, agree to the research terms specified above with the exception of the following rules, policies and procedures: _________________________________________________________________________________ _________________________________________________________________________________ _________________________________________________________________________________ I agree to pay _______ hrs X $25 per hour for a total of $ ________ to research the above goal. Signature ______________________________________________ Date __________________________________________________ I, Genealogist, agree to the research terms specified above. Signature _________________________________________________ Date _____________________________________________________
Sample 1
AutoNDA by SimpleDocs
Research Goal. It is the intent of this thesis to evaluate the association of maternal mortality with seat belt use and motor vehicle crashes in pregnant women. Former Director-General of the World Health Organization, Xxx Xxxx- wook, April 2005: Mothers, newborn and children represent the well- being of a society and its potential for the future. Their health needs cannot be left unmet without harming the whole of society (World Health Report, 2005).
Sample 1
Research Goal. The goal of the Parties’ research under this Agreement will be to generate data and results regarding the use of Codiak Licensed Know-How and of the Codiak Materials to (a) discover and research Exosome therapeutics that include Codiak Materials or Sarepta Materials and that are directed to the Research Targets and (b) generate data and results therefrom to help Sarepta assess whether to exercise a Sarepta Option hereunder, in each case, in accordance with the Research Plan.
Sample 1
Research Goal. The objective of this study was to define the relationship between circulating heme and the heme degradation pathway in ACS pathogenesis and severity by establishing a measurable biomarker that is predictive of severe ACS risk with the future goal to improve prognosis. If successful, then we would have identified a biomarker to facilitate early intervention and management of severe ACS, and thereby reduce morbidity and mortality in SCD. We tested our hypothesis that “Unscavenged circulating heme increases the risk of severe ACS in children with SCD” using 2 interrelated specific aims: [1]: To determine the association between plasma levels of individual heme degradation biomarkers; total plasma heme (TPH), plasma free heme (PFH), plasma HO-1, plasma Hemopexin (Hx) during ACS and compare with their corresponding plasma levels at steady state. [2]: To determine the association between each individual heme degradation biomarkers [total plasma heme (TPH), plasma free heme (PFH), plasma HO-1, and plasma Hemopexin (Hx)] with severe ACS. Study Design: Our overall strategy was to study SCD patients admitted to the hospital with ACS to define the relationship between circulating free heme, markers of heme degradation and severe ACS, using a cross sectional study design. Eligible patients with a confirmed diagnosis of SCD and ACS were recruited from the three hospitals of Children’s Healthcare of Atlanta: Xxxxxxxx, Scottish-Rite and Xxxxxx Spalding, which provides care for over 1,800 children and adolescents with SCD in the metro Atlanta area. According to the National Acute Chest Syndrome Study Group, the incidence of ACS in our patient population is approximately 20%. Eligible SCD patients admitted to the hospital with ACS or who develop ACS during admission were enrolled on study for a 3-year period (2015-2018) in the HOP-ACS Study. Patients were recruited within 48 hours of ACS diagnosis and informed consent or assent (where applicable) was obtained to the HOP- ACS protocol approved by the Emory Institutional Review Board (IRB) [IRB00047246]. ACS was defined as a new pulmonary infiltrate detected by chest radiograph (CXR) and associated with any of the following symptoms alone or in combination; pain (particularly chest/back), fever, hypoxia and /or difficulty breathing. Characteristics of the study population: SCD patients admitted to the hospital with ACS or who develop ACS during admission from December, 2015 to 2018, were identified based on the following cr...
Sample 1
Research Goal. The general goal of the COHERENO project is to map structures for successful collaboration between contractors and other supply actors that are involved in nearly zero-energy building (nZEB) single family home (SFH) renovations. To support this general goal, it is the goal of this work to detect most potential customer segments (of owner-occupants) for nZEB SFH renovations and to identify characteristics of customers (in this case innovators and early adopters) that are similar in ways relevant to business modelling (like for example for the definition of customer values).
Sample 1
Research Goal. The general goal of this thesis is to address the extent to which the forms of officially planned abandonment and neglect described above are indeed potentially harmful and represent a recipe for the collapse of war survivors who have to struggle to repair their own lives amidst shattered families and communities. In particular, this study explores the ways in which war survivors, amidst the extreme legacies of war and the post-war official neglect of these legacies, have been able to make use of locally available and accessible resources to develop strategies to engage in and to attain reconciliation and healing. Furthermore, the effectiveness of some of these strategies is studied.
Sample 1

Related to Research Goal

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Commercial Milestones In partial consideration of the rights granted by AstraZeneca to Licensee hereunder, Licensee shall pay to AstraZeneca the following payments, which shall be non-refundable, non-creditable and fully earned upon the first achievement of the applicable milestone event:

  • Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section 2.4.2.4 will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

Time is Money Join Law Insider Premium to draft better contracts faster.